• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Unum Therapeutics appoints Jörn Aldag to board of directors

Unum Therapeutics appoints Jörn Aldag to board of directors

February 10, 2016
CenterWatch Staff

Unum Therapeutics, a company developing a universal cellular immunotherapy to treat multiple cancers, has appointed Jörn Aldag to its board of directors. Aldag brings over two decades of experience leading innovative biotech companies.

“Jörn is one of the true pioneers in building companies that bring novel and potentially curative therapies to patients with severe conditions, and we are very excited to have him join our board,” said Chuck Wilson, Ph.D., president and CEO of Unum Therapeutics. “With his experience, I expect Jörn to provide invaluable insights to our team as we continue to build Unum, seek to bring our Antibody-Coupled T-cell Receptor (ACTR) therapy to patients, and work to change the way cancer is treated.”

Aldag currently is the chairman of Molecular Partners, Zurich, Switzerland—a company developing a new class of small protein therapies called DARPins. Until recently, he was the chief executive officer of the gene therapy company uniQure, the first company to ever receive approval of a gene therapy product from a Western regulatory agency.

“As cellular immunotherapies emerge as one of the most promising approaches in oncology, Unum’s leadership team and ACTR technology position the company for success,” said Aldag. “I am looking forward to working with the board and Unum’s management during the next phase of the company’s growth.”

Before his tenure at uniQure, Aldag was president and CEO of Evotec, a company focused on small molecule drug discovery. There he successfully developed a pipeline of CNS programs and drove the acquisitions of LSE-listed Oxford Asymmetry and NASDAQ-listed Renovis.

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing